Impact of benzodiazepine consumption reduction on future burden of dementia.
Aged
Aged, 80 and over
Anti-Anxiety Agents
/ adverse effects
Benzodiazepines
/ adverse effects
Cohort Studies
Dementia
/ chemically induced
Female
France
/ epidemiology
Humans
Hypnotics and Sedatives
/ adverse effects
Incidence
Life Expectancy
Male
Monte Carlo Method
Prevalence
Risk Factors
Sex Factors
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 09 2020
04 09 2020
Historique:
received:
24
09
2019
accepted:
30
07
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
20
3
2021
Statut:
epublish
Résumé
Dementia is a major public health issue worldwide and chronic use of benzodiazepine, which is very frequent in northern countries, was found to be a risk factor of dementia. This work aims at evaluating the impact of a reduction in chronic use of benzodiazepine on the future burden of dementia in France. Using estimations of dementia incidence and of benzodiazepine use and nation-wide projections of mortality and population sizes, a Monte Carlo approach based on an illness-death model provided projections of several indicators of dementia burden. With no change in benzodiazepine consumption, the prevalence of dementia between age 65 and 99 in France in 2040 was estimated at 2.16 millions (95% confidence interval (CI) 1.93-2.38), with a life expectancy without dementia at 65 years equal to 25.0 years (24.7-25.3) for women and 23.8 years (23.5-24.2) for men. Assuming a disappearance of chronic use of benzodiazepine in 2020, the prevalence would be reduced by about 6.6% in 2040 and the life expectancy without dementia would increase by 0.99 (0.93-1.06) year among women and 0.56 (0.50-0.62) among men. To conclude, a modest but significant reduction in future dementia burden could be obtained by applying current recommendation for duration of benzodiazepine use.
Identifiants
pubmed: 32887900
doi: 10.1038/s41598-020-71482-0
pii: 10.1038/s41598-020-71482-0
pmc: PMC7474098
doi:
Substances chimiques
Anti-Anxiety Agents
0
Hypnotics and Sedatives
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14666Références
Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005).
pubmed: 16360788
pmcid: 2850264
Association, A. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement 8, 131–168 (2012).
Winblad, B. et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 15, 455–532 (2016).
pubmed: 26987701
Bellou, V. et al. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. Alzheimers Dement 13, 406–418 (2017).
pubmed: 27599208
Chen, P. L., Lee, W. J., Sun, W. Z., Oyang, Y. J. & Fuh, J. L. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS ONE 7, e49113 (2012).
pubmed: 23145088
pmcid: 3492301
Lagnaoui, R. et al. Benzodiazepine use and risk of dementia: a nested case-control study. J. Clin. Epidemiol. 55, 314–318 (2002).
pubmed: 11864804
Wu, C. S., Wang, S. C., Chang, I. S. & Lin, K. M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am. J. Geriatr. Psychiatry 17, 614–620 (2009).
pubmed: 19546656
Gallacher, J. et al. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J. Epidemiol. Community Health 66, 869–873 (2012).
pubmed: 22034632
Billioti de Gage, S. et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 345, e6231 (2012).
pubmed: 23045258
pmcid: 3460255
Billioti de Gage, S. et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 349, g5205 (2014).
pubmed: 25208536
pmcid: 4159609
Gomm, W. et al. Regular benzodiazepine and Z-substance use and risk of dementia: an analysis of German claims data. J. Alzheimers Dis. 54, 801–808 (2016).
pubmed: 27567804
Shash, D. et al. Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study. Alzheimers Dement. 12, 604–613 (2016).
pubmed: 26602630
Taipanen, V. T. H., Tanskanen, A., Tiihonen, J., Hartikainen, S. & Tolppanen, A. M. The risk of Alzheimer’s disease associated with benzodiazepines and related drugs: a nested case-control study. Acta Psychiatr. Scand. 138, 91–100 (2018).
Grossi, C. M. et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatr. 19(1), 276 (2019).
pubmed: 31638906
pmcid: 6802337
Osler, M. & Jørgensen, M. B. Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. Am. J. Psychiatry 177, 497–505 (2020).
pubmed: 32252539
Islam, M. M. et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47, 181–191 (2016).
pubmed: 28013304
Penninkilampi, R. & Eslick, G. D. A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs 32, 485–497 (2018).
pubmed: 29926372
He, Q., Chen, X., Wu, T., Li, L. & Fei, X. Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies. J. Clin. Neurol. 15(1), 9–19 (2019).
pubmed: 30375757
Billioti de Gage, S., Pariente, A. & Bégaud, B. Is there really a link between benzodiazepine use and the risk of dementia?. Expert Opin. Drug Saf. 14, 733–747 (2015).
pubmed: 25691075
Donoghue, J. & Lader, M. Usage of benzodiazepines: a review. Int. J. Psychiatry Clin. Pract. 14, 78–87 (2010).
pubmed: 24922466
Olfson, M., King, M. & Schoenbaum, M. Benzodiazepine use in the United States. JAMA Psychiatry 72, 136–142 (2015).
pubmed: 25517224
Kurko, T. A. et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns—a systematic review of register-based studies. Eur. Psychiatry 30, 1037–1047 (2015).
pubmed: 26545257
Pariente, A. et al. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 25, 61–70 (2008).
pubmed: 18184030
Joly, P. et al. Prevalence projections of chronic diseases and impact of public health intervention. Biometrics 69, 109–117 (2013).
pubmed: 23379687
Ahmadi-Abhari, S. et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. BMJ 358, j2856 (2017).
pubmed: 28679494
pmcid: 5497174
Brookmeyer, R., Abdalla, N., Kawas, C. H. & Corrada, M. M. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement. 14, 121–129 (2018).
pubmed: 29233480
Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337–1342 (1998).
pubmed: 9736873
pmcid: 1509089
Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 3, 186–191 (2007).
pubmed: 19595937
Mura, T., Dartigues, J. F. & Berr, C. How many dementia cases in France and Europe? Alternative projections and scenarios 2010–2050. Eur. J. Neurol. 17, 252–259 (2010).
pubmed: 19796284
Jacqmin-Gadda, H. et al. 20-Year prevalence projections for dementia and impact of preventive policy about risk factors. Eur. J. Epidemiol. 28, 493–502 (2013).
pubmed: 23756781
Wanneveich, M., Jacqmin-Gadda, H., Dartigues, J. F. & Joly, P. Impact of intervention targeting risk factors on chronic disease burden. Stat. Methods Med. Res. 27, 414–427 (2018).
pubmed: 26988925
Power, M. C. et al. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 22, 646–659 (2011).
pubmed: 21705906
pmcid: 3640480
Tolppanen, A. M., Solomon, A., Soininen, H. & Kivipelto, M. Midlife vascular risk factors and Alzheimer’s disease: evidence from epidemiological studies. J. Alzheimers Dis. 32, 531–540 (2012).
pubmed: 22842867
Dartigues, J. et al. The paquid epidemiological program on brain ageing. Neuroepidemiology 11(suppl 1), 14–18. https://doi.org/10.1159/000110955 (1992).
doi: 10.1159/000110955
pubmed: 1603241
Moulis, G. et al. French health insurance databases: what interest for medical research?. La Revue de médecine interne 36(6), 411–417 (2015).
pubmed: 25547954
Bachhuber, M. A., Hennessy, S., Cunningham, C. O. & Starrels, J. L. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am. J. Public Health 106, 686–688 (2016).
pubmed: 26890165
pmcid: 4816010
Blanpain, N. & Buisson, G. Projections de population 2013–2070 pour la France (Insee, 2016).
Mathieu, C. et al. A. Excess of all-cause mortality associated with benzodiazepine use: a cohort study. Submitted.
Joly, P., Commenges, D., Helmer, C. & Letenneur, L. A penalized likelihood approach for an illness-death model with interval-censored data: application to age-specific incidence of dementia. Biostatistics. 3, 433–443 (2002).
pubmed: 12933608
Touraine, C., Gerds, T. A. & Joly, P. The SmoothHazard package for R: Fitting regression models to interval-censored observations of illness-death models. J. Stat. Softw. 79, 1–22 (2017).
Wolters, F. J. et al. Life expectancy with and without dementia: a population-based study of dementia burden and preventive potential. Am J Epidemiol. 188, 372–381 (2019).
pubmed: 30299452
Rothman, K. J., Greenland, S. & Lash, T. L. Modern epidemiology (Lippincott Williams & Wilkins, Philadelphia, 2008).
Pariente, A., Billioti de Gage, S., Moore, N. & Bégaud, B. The benzodiazepine-dementia disorders link: current state of knowledge. CNS Drugs 30, 1–7 (2016).
pubmed: 26715389
Brandt, J. & Leong, C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R&D 17, 493–507 (2017).
Tampi, R. R. & Tampi, D. J. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am. J. Alzheimer’s Dis. Other Dement. 29, 565–574 (2014).
Rubino, A. et al. Association of the US food and drug administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia. JAMA Netw. Open 3(4), e203630–e203630 (2020).
pubmed: 32343351
pmcid: 7189225